Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2001-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill
liver cancer cells.
PURPOSE: Phase II trial to study the effectiveness of doxorubicin and interleukin- 2 in
treating patients who have liver cancer that cannot be removed by surgery.